FMP
Silexion Therapeutics LTD
SLXN
NASDAQ
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
0.845 USD
0.021 (2.49%)
SLXN Financial Statements
Year
2024
2023
2022
Total Revenue
0
0
0
Cost of Revenue
0
0
0
Gross Profit
0
0
0
Operating Expenses
12.57M
4.68M
3.86M
Research and Development
5.82M
3.71M
3.23M
Selling, General & Administrative Expenses
6.76M
928k
577k
Selling & Marketing Expenses
0
0
0
General & Administrative Expenses
6.76M
928k
577k
Other Expenses
0
45k
57k
Operating Income
0
-4.68M
-3.86M
Total Other Income/Expenses Net
0
-395k
396k
Income Before Tax
16.51M
-5.08M
-3.46M
Income Tax
0
32k
24k
Net Income
16.51M
-4.94M
-3.21M
Basic EPS
2.03
-0.61
-0.39
EPS Diluted
2.03
-0.61
-0.39
Basic Average Shares
8.15M
8.15M
8.15M
Diluted Average Shares
8.15M
8.15M
8.15M
EBITDA
0
-4.64M
-3.8M
Retained Earning Schedule
Year
2024
2023
Retained Earnings (Previous Year)
-26.81M
-21.87M
Net Income
16.51M
-4.94M
Stock Repurchases
0
0
Dividend Paid
0
0
Retained Earnings
-43.25M
-26.81M
Other Distributions
-16.44M
-4.94M
PPE Schedule
Year
2024
2023
Gross PPE
560k
247k
Annual Depreciation
0
45k
Capital Expenditure
-22k
-12k
Net PPE
582k
214k
Intangible and Goodwill Schedule
Year
2024
2023
Acquisitions and Adjustments
0
0
Goodwill (Previous Year)
0
0
Goodwill
0
0
All figures are in USD.
